written on 19.06.2014
Tags:
,

Will Allergan scramble for Shire to beat off Valeant's hostile advance?

TAGS: ,

Valeant has been promising a hostile takeover approach for Allergan since the company's board unanimously shot down its $53 billion cash-and-stock bid. And now, it's made its first move.

Latest Report